[go: up one dir, main page]

WO1999011791A3 - Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents - Google Patents

Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents Download PDF

Info

Publication number
WO1999011791A3
WO1999011791A3 PCT/US1998/018393 US9818393W WO9911791A3 WO 1999011791 A3 WO1999011791 A3 WO 1999011791A3 US 9818393 W US9818393 W US 9818393W WO 9911791 A3 WO9911791 A3 WO 9911791A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligands
necrosis factor
tumor necrosis
nucleic acids
binding agents
Prior art date
Application number
PCT/US1998/018393
Other languages
French (fr)
Other versions
WO1999011791A2 (en
Inventor
Preet M Chaudhary
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Priority to AU93764/98A priority Critical patent/AU9376498A/en
Publication of WO1999011791A2 publication Critical patent/WO1999011791A2/en
Publication of WO1999011791A3 publication Critical patent/WO1999011791A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides novel receptors of the tumor necrosis factor receptor family as well as ligands of the tumor necrosis factor family. In addition to the isolated receptors and ligands of the invention, there are provided encoding nucleic acids and related selective binding agents.
PCT/US1998/018393 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents WO1999011791A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU93764/98A AU9376498A (en) 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92463497A 1997-09-05 1997-09-05
US08/924,634 1997-09-05

Publications (2)

Publication Number Publication Date
WO1999011791A2 WO1999011791A2 (en) 1999-03-11
WO1999011791A3 true WO1999011791A3 (en) 1999-09-30

Family

ID=25450466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018393 WO1999011791A2 (en) 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents

Country Status (2)

Country Link
AU (1) AU9376498A (en)
WO (1) WO1999011791A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902910B2 (en) 1997-01-28 2005-06-07 Human Genome Sciences, Inc. Death domain containing receptor 4
US7314619B2 (en) 1997-05-15 2008-01-01 Genentech, Inc. Inducing apoptosis using anti-Apo-2 antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7402658B2 (en) 1997-09-12 2008-07-22 Biogen Idec Ma Inc. TRAIN-R: a cysteine-rich member of the TNF-receptor family
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
AU729062C (en) 1997-01-14 2004-03-25 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha & 6beta
EP0857782A3 (en) * 1997-01-27 1999-12-22 Smithkline Beecham Corporation Novel mammalian DD-1 gene
DE69837806T3 (en) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "DEATH-DOMAIN" -INTERDENTING RECEPTOR 4 (DR4), A MEMBER OF THE TNF-RECEPTOR SUPERFAMILY, BINDING ON TRAIL (APO-2L)
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
JP4303883B2 (en) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド TNFR homologue of DcR3 polypeptide
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
EP1044267A2 (en) * 1997-12-29 2000-10-18 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
DE19809978A1 (en) * 1998-03-09 1999-09-16 Basf Ag New soluble member of tumor necrosis factor receptor family, useful for identification specific modulators and for treating disease e.g. tumors
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AU1467000A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP1141027A1 (en) 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
PL198934B1 (en) 1999-01-25 2008-08-29 Apoxis Sa Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2574200A (en) * 1999-02-19 2000-09-04 Toshio Kitamura Novel tnf receptor-like proteins
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2001004139A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
MXPA02001264A (en) 1999-08-04 2002-07-22 Amgen Inc Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY.
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
EE05673B1 (en) 1999-08-17 2013-08-15 Biogen, Inc. BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
WO2001030850A1 (en) * 1999-10-22 2001-05-03 Zymogenetics, Inc. Umlr polypeptides
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
NZ520598A (en) * 2000-02-11 2004-04-30 Inst Genetics Llc TRADE molecules and uses related thereto
EP1263788A2 (en) * 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
ES2267593T3 (en) 2000-02-16 2007-03-16 Genentech, Inc. ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS.
SI2857516T1 (en) 2000-04-11 2017-09-29 Genentech, Inc. Multivalent antibodies and uses therefor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US6943146B2 (en) 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
ES2287130T3 (en) 2000-05-12 2007-12-16 Amgen Inc. POLYPEPTIDES TO INHIBIT THE PROLIFERATION OF CELLS B AND T INDUCED BY APRIL.
ES2358885T3 (en) 2000-06-16 2011-05-16 Human Genome Sciences, Inc. ANTIBODIES THAT BIND BLyS IMMUNO-SPECIFICALLY.
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
DE60136816D1 (en) 2000-07-27 2009-01-15 Genentech Inc SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
NZ529267A (en) 2001-05-11 2006-05-26 Amgen Inc Peptides and related molecules that bind to tall-1
US7189820B2 (en) 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
EP2116259B1 (en) 2001-05-24 2012-01-25 ZymoGenetics, Inc. TACI-immunoglobulin fusion proteins
EP1572874B1 (en) 2001-05-25 2013-09-18 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DK1409544T3 (en) 2001-07-03 2009-10-26 Genentech Inc Human DR4 antibodies and uses thereof
WO2003013578A1 (en) * 2001-08-07 2003-02-20 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003029420A2 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
JP2005521640A (en) 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Apo-2 ligand / TRAIL formulation
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US20060240004A1 (en) 2002-04-09 2006-10-26 Linda Burkly Methods for treating tweak-related conditions
AU2003247609A1 (en) 2002-06-24 2004-01-06 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
CN101899106A (en) * 2002-10-29 2010-12-01 阿纳福公司 The binding proteins for trimeric of trimerization cytokine
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CN101014245A (en) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 Taj in neuronal function
JP5237638B2 (en) 2004-08-06 2013-07-17 ジェネンテック， インコーポレイテッド Assays and methods using biomarkers
JP5140421B2 (en) 2004-08-06 2013-02-06 ジェネンテック， インコーポレイテッド Assays and methods using biomarkers
AU2005295713B2 (en) 2004-10-13 2011-06-16 The Washington University Use of BAFF to treat sepsis
WO2006067210A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
JP5562521B2 (en) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション Agents and methods relating to reducing resistance to apoptosis-inducing death receptor agonists
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
ES2432564T3 (en) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Treatment and evaluation of inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
DK1915626T3 (en) 2005-08-16 2012-02-13 Genentech Inc Apoptosis Sensitivity to Apo2L / TRAIL by Testing for GalNac-T14 Expression in Cells / Tissues
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007092777A2 (en) * 2006-02-02 2007-08-16 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
WO2007134326A2 (en) 2006-05-15 2007-11-22 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
US20100105620A1 (en) 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
CN102666588A (en) 2009-11-05 2012-09-12 Uab研究基金会 Treatment of basal cell-like genotypic cancers
KR20140015152A (en) 2009-12-02 2014-02-06 악셀레론 파마 인코포레이티드 Compositions and methods for increasing serum half-life of fc fusion proteins
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
ES2675847T3 (en) 2010-10-29 2018-07-13 Daiichi Sankyo Company, Limited New anti-DR5 antibody
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
EP3323428A1 (en) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4
WO1998038304A1 (en) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Novel polypeptide, dna encoding the same and use thereof
WO1998041629A2 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
WO1998051793A1 (en) * 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998058062A1 (en) * 1997-06-18 1998-12-23 Genentech, Inc. Apo-2DcR
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4
WO1998038304A1 (en) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Novel polypeptide, dna encoding the same and use thereof
WO1998041629A2 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
WO1998051793A1 (en) * 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998058062A1 (en) * 1997-06-18 1998-12-23 Genentech, Inc. Apo-2DcR
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHICHEPORTICHE Y. ET AL.: "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis", J. BIOL. CHEM., vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 32401 - 32410, XP002108889 *
CHINNAIYAN A M ET AL: "SIGNAL TRANSDUCTION BY DR3, A DEATH DOMAIN-CONTAINING RECEPTOR RELATED TO TNFR-1 AND CD95", SCIENCE, vol. 274, no. 5289, 8 November 1996 (1996-11-08), pages 990 - 992, XP000676685 *
DATABASE GENBANK 19 July 1996 (1996-07-19), MARRA M. ET AL.: "Mouse embryo EST clone IMAGE:427152", XP002093795 *
DATABASE GENBANK 26 August 1996 (1996-08-26), MARRA M. ET AL.: "Mouse embryo EST clone IMAGE:472300", XP002093796 *
MACFARLANE M ET AL: "IDENTIFICATION AND MOLECULAR CLONING OF TWO NOVEL RECEPTORS FOR THE CYTOTOXIC LIGAND TRAIL", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 41, 10 October 1997 (1997-10-10), pages 25417 - 25420, XP002065148 *
PAN G ET AL: "AN ANTAGONIST DECOY RECEPTOR AND A DEATH DOMAIN-CONTAINING RECEPTOR FOR TRAIL", SCIENCE, vol. 277, 8 August 1997 (1997-08-08), pages 815 - 818, XP002065147 *
ROKHLIN O.W. ET AL.: "Fas-mediated apoptosis in human prostatic carcinoma cell lines", CANCER RESEARCH, vol. 57, no. 9, 1 May 1997 (1997-05-01), pages 1758 - 1768, XP002093791 *
SHERIDAN J P ET AL: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors", SCIENCE, no. 277, 8 August 1997 (1997-08-08), pages 818 818, XP002075799 *
USLU R. ET AL.: "Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis", CLIN. CANCER RESEARCH, vol. 3, no. 6, June 1997 (1997-06-01), pages 963 - 972, XP002093792 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902910B2 (en) 1997-01-28 2005-06-07 Human Genome Sciences, Inc. Death domain containing receptor 4
US7314619B2 (en) 1997-05-15 2008-01-01 Genentech, Inc. Inducing apoptosis using anti-Apo-2 antibodies
US7595046B2 (en) 1997-05-15 2009-09-29 Genentech, Inc. Treatment of cancer using anti-Apo-2 antibodies
US7402658B2 (en) 1997-09-12 2008-07-22 Biogen Idec Ma Inc. TRAIN-R: a cysteine-rich member of the TNF-receptor family
US7838639B2 (en) 1997-09-12 2010-11-23 Biogen Idec Ma Inc. Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies

Also Published As

Publication number Publication date
WO1999011791A2 (en) 1999-03-11
AU9376498A (en) 1999-03-22

Similar Documents

Publication Publication Date Title
WO1999011791A3 (en) Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO2000001815A3 (en) Neurotrophic factors
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
CA2200423A1 (en) Novel estrogen receptor
AU9013998A (en) Tumor necrosis factor receptor ztnfr-5
WO1999015653A3 (en) Tie ligand homologues
DE69805237D1 (en) Tumor necrosis associated receptor, TR4
WO2001096565A3 (en) Binding agents: chimeric ligand/receptor proteins
NL1010890C2 (en) Stabilizer mixture.
WO2002072826A3 (en) Neurotrophic factors
GB9807256D0 (en) Functional protein compositions,emulsions based thereon and processes for their preparation
ZA9710288B (en) Novel genes encoding telomerase proteins.
WO1997011968A3 (en) A gene associated with liver neoplastic disease
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
DE69841176D1 (en) Rtd receptor
AU3208699A (en) P40 protein acts as an oncogene
AU2190801A (en) Binding protein
WO2001012664A3 (en) Notch receptor ligands and uses thereof
ZA992214B (en) Oligomeric stabilizer mixture.
AU9130598A (en) Tumor necrosis factor receptor ztnfr-6
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
WO1998017827A3 (en) Compositions and methods using eukaryotic rad52
PL339256A1 (en) Kindling mixture

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA